Poziotinib treats HER2 Exon20 inserted mutation non-small cell lung cancer: THE ZENITH20 trial yielded positive results.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Spectrum, !---- a biopharmaceutical company, announced today that Phase II Clinical Trials (ZENITH20) have reached the primary end point, evaluating the effectiveness and safety of Poziotinib in treating patients with HER2 exosome 20 (Exon20) inserted mutation sized non-small cell lung cancer (NSCLC).Poziotinib is a new epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the activity of EGFR and tyrosine kinase as well as HER2 and HER4. "We see Poziotinib as a significant step forward for patients with this deadly disease," said Joe Turgeon, president and chief executive officer ofSpectrum Pharmaceuticals.results showed that the median time of remission was 5.1 months and the median follow-up time was 8.3 months.disease control rate (DCR) was 70%, with a median progression-free survival of 5.5 months.safety was consistent with adverse events seen in other second-generation EGFR tyrosine kinase inhibitors, with a 3-level rash associated with treatment, a 3-level incidence of diarrhea, and an unreported pneumonia (0/90)..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
